u-Tumor growth is dependent on the abi]ity of neoplastic cells to induce angiogenesis. Blood-vesselremodeling requires the reconstruction of the nonflbrous proteins and type IV collagen components of the basement membrane. This study has assessed the influence of the growth of C6 astrocytoma cells in the rat spheroid implantation model on serum general protease and type IV collagenase activity. The results demonstrate that general protease activity increased in serum, reaching maximum values on Day 6 and Day 13 following spheroid implantation, and that type IV collagenase activity increased in serum, obtaining maximum values on Day 8 and Day 15. The measurement of serum proteolytic activity may be of value in the detection of recurrent tumors.
T
UMOR growth is dependent on the ability of neoplastic cells to coordinate a complex anglogenesis cascade, s,Jj This results in the remodeling of normal cerebral microvessels into morphologically distinct tumor microvessels. 8 '32 The initiation stage of angiogenesis involves the degradation and reconstruction of basement membrane components of cerebral microvessels, which usually occurs before endothelialcell proliferation. 8~22 Nonfibrous protein components such as laminin, adhesive molecules, and proteoglycans are integral components of the normal basement membrane. 3"27' 29 Type IV collagen may constitute up to 90% of the total protein of the basement membrane and forms a fibrous matrix that confers structural integrity to the vessel wall. s2" To assess the degradation and remodeling of basement membrane components during tumor-associated angiogenesis, the levels should be measured both of general or nonspecific proteolytic activity, which degrades the nonfibrous protein components of the basement membrane, and of type IV collagenase activity, which degrades intrinsic type IV collagen, v,~5,3~, A cell line derived from a human malignant glial tumor, U-251, contains and releases general protease and type IV collagenase activity during monolayer culture. 7 Our previous studies have demonstrated that the malignant rat astrocytic cell line, C6 astrocytoma, releases both general protease and type IV collagenase activity extracellularly during the exponential growth of C6 astrocytoma cells in monolayer culture. 36 The levels of nonspecific proteolytic and type IV collagenase activity are altered in peritumoral and tumor tissues during the growth of C6 astrocytoma in the rat spheroid implantation model. 35 General proteolytic activity was also enhanced in cerebral tissue contralateral to the tumor. These results suggest that malignant glial cells growing in tissue culture and in vivo may influence proteolytic activity in a number of different microenvironments.
A number of protein tumor markers, such as alphafetoprotein and human chorionic gonadotropin, have been found increased in intracranial germ-cell tumor tissue ~7 and in the cerebrospinal fluid and serum of these patients? '7 High levels of serum collagenase has been associated with premature labor, and the measurement of this activity has been suggested as a potential biochemical marker. 2~~s Considering that C6 astrocytoma cells release proteolytic enzymes into the extracellular environment and the growth of these cells in vivo is associated with high tumor and peritumoral levels of these activities, it appeared reasonable to hypothesize that serum levels of proteolytic activity may be altered during some phases of the growth of C6 cells in vivo. The presence of increased serum proteolytic activity associated with the growth of C6 astrocytoma in vivo could be explained by: 1) increased serum content of proteolytic enzymes; 2) decreased intrinsic serum antiproteolytic activity; or 3) a combination of both of these processes. The purpose of these experiments was to assess the levels of general protease and type IV collagenase activity in serum during the growth of C6 astrocytoma cells in the rat spheroid implantation model.
Materials and Methods

Implantation of C6 Astrocytoma Spheroids
Spheroids of C6 astrocytoma cells were grown in spinner flasks, and single spheroids (350 to 400 um in diameter) were implanted into the cerebral cortex of Sprague-Dawley rats as previously describedfl '~ A small lesion was created in the rat cerebral cortex to introduce the spheroid. Two control rat groups were required: one received no surgical procedure, and in the second a lesion was produced in the cerebral cortex but no spheroid was implanted. The in vivo growth of C6 astrocytoma spheroids and serum proteolytic activity were monitored during 18 days of tumor growth. Tumor wet weights were assessed in milligrams.'~
Preparation of Serum
The serum was obtained from the same rats that provided the cerebral tissue. The serum was diluted 1:100 using buffer (50 mM Tricine, 0.2 NaC1, 10 mM CaC12, pH 7.5), centrifuged at 1200 G for 5 minutes, and stored at 4~ until used. For each enzyme assay, l to 3 ul of this solution was used. Serum samples from control animals and tumor-bearing animals were analyzed simultaneously.
General Protease and Type IV Collagenase Activity
Proteolytic activity was assayed by measuring the degradation of~H-a-casein and 3H-type IV collagen to products soluble in trichloroacetic acid. The a-casein and human type IV collagen were labelled as previously described. 7"34"37 The assays contained between 1 and 3 ug of protein to maintain activity within the linear range. One unit of activity represents the amount of enzyme required to solubilize 1 #g/hr of a-casein or 1 #g/hr of type IV collagen at 37~ Specific activity is expressed as units per milligram of protein.
Protein Assay
The method of Bradford 4 utilizing a protein assay kit* was used to determine protein levels in the serum samples. A standard curve was constructed based on bovine serum albumin.
* Protein assay kit manufactured by Bio-Rab Laboratories, Richmond, California.
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Statistical Analysis
The results reported in this study are expressed as means _+ standard error of the means. Statistical significance was determined using Student's unpaired t-test multiple comparisons; a p value of less than 0.01 was considered significant.
Results
General Prmease Activity in Serum During Tumor Growth
Tumor growth in the C6 astrocytoma implantation model is characterized by an initial slow rate of growth for a period of 8 days postimplantation; subsequently, a faster growth rate occurred between Days 8 and 15.9.,o.37 Rapid growth was observed between 15 and 18 days following implantation (Fig. 1 left) .
A basal level of serum general protease activity was detected in normal adult Sprague-Dawley rats ( Fig. 1 left). The creation of a cerebral defect without the implantation of a spheroid (lesion-only control animals) was not associated with significant alterations of general protease activity in serum compared with nonoperated control group levels. During tumor growth two significant peaks of general protease activity were seen in serum; the first occurred on Day 6 and a second smaller peak on Day 13.
Type IV Collagenase Activity in Serum During Tumor Growth
Serum levels of type IV collagenase activity were monitored during tumor growth ( Fig. 1 right) . Low basal levels of type IV coUagenase activity can be measured in rat serum. Lesion-only control animals did not have a significant alteration in serum type IV collagenase activity compared with nonoperated control rats. Two peaks of type IV collagenase activity were observed during the growth of C6 astrocytoma in vivo. The initial peak occurred on Day 8 and a second smaller peak was seen on Day 15.
Discussion
This study has demonstrated that the growth of C6 astrocytoma cells in the spheroid implantation model is associated with an increase in serum general protease and type IV col!agenase activity. The increased serum proteolytic activity measured is dependent on the presence of an implanted C6 astrocytoma spheroid since no significant alterations in serum proteolytic activity was seen in the lesion-only controls. The experiment was limited to 18 days so that secondary events such as extensive tumor necrosis or hemorrhage, which occur late in this model, 9''~ could not influence serum proteolytic activity.
Degradation of the Basement Membrane
The basement membrane of cerebral microvessels is a complex structure in which a number of nonfibrous and fibrous proteins are integrated. A model of its General proteases may be necessary, to expose the type IV collagen of basement membrane to type IV collagenase activity? 5 The general proteolytic activity released by C6 astrocytoma cells in vitro appears to involve at least two distinct activities, a cysteine protease and a manganese-stimulated protease (R Cook, unpublished data). The role that these enzymes play in the total general proteolytic activity of in vivo C6 astrocytoma is not known. The contribution by activated inflammatory cells such as polymorphonuclear leukocytes, macrophages, and monocytes to the proteolytic degradation of basement membranes in this model has not been ascertained; however, inflammatory cells can release a number of proteases, 2~22353~ which may play a role in these events.
Type IV collagenase is an important protein component of the vascular basement membrane of both normal cerebral vessels -~7 and microvessels associated with malignant gliomas. 22 A number of structurally related matrix metalloproteinases containing zinc at their active center can degrade type IV collagen. 3~ These include a 92-kD gelatinase, a 72-kD type IV collagenase, transin (48 kD), and transin 2 (47 kD) which are the rat homologues of human stromelysin and stromelysin 2. ~'38 These enzymes appear to be regulated by a variety of mechanisms. All of these enzymes are secreted in a proenzyme or zymogen form and are activated by the cleavage of a specific portion of the molecule by proteases or organomercurials. 2~3~ The growth of C6 astrocytoma cells in culture or in vivo was associated with substantial type IV collagenase activity. 35,3~ Although the zymogen forms of these enzymes have some activity, the presence of substantial type IV collagenase activity associated with C6 astrocytoma cells would suggest that mechanisms are available for activation of these enzymes both in vitro and in vivo. 3~ It is not known if the general protease activity associated with C6 astrocytoma cells plays any role in the activation of the zymogen forms of these metalloproteinases. Although the contribution of individual metalloproteinases to type IV collagen degradation in this model have not been ascertained, studies using elution profiles of type IV collagen activity on a Mono Q column suggest that the major metalloproteinase present in the supernatant of C6 astrocytoma ceils is about 70 kD in size (IS Vaithilingam, unpublished data). This activity would be more consistent with the 72-kD type IV collagenase than with any of the other metalloproteinases that can degrade type IV collagen in the rat.
Two different tissue inhibitors of matrix metalloproteinases (TIMP's) inhibit the function of all metalloproteinases presently known to occur in tissues. 6'~3'3~
The 92-kD gelatinase appears to be inhibited more by TIMP, whereas TIMP-2 may be more effective at inhibiting the 72-kD collagenase.~ In vivo, the total extracellular collagenolytic activity expressed is a balance between a number of different activating and inhibiting mechanisms. The contribution of specific enzymes or their inhibitors to the degradation of type IV collagen in the model assessed in this study is not known, but is presently being studied.
Serum General Proteolytic A ctiviO'
Many of the proteases found extracellularly are released as a response mechanism to physical inju~' or to the presence of foreign proteins in the circulation, and these are called "acute phase reactants. ''~62~ The presence of active proteases in the general circulation would appear to pose some risk to all cells. The serum contains a number of proteolytic inhibitors (termed "serpins").~'2~ The majority of these inhibitors regulate the serine proteases involved in coagulation, fibrinolysis complement activation, and phagocytosis. Antiproteinases such as ~-proteinase inhibitor (c~-antit~psin), mantichymotrypsin, and antithrombin Ill are the most common of a wide number of compounds that have been assessed. -~~ In rats c~-macroglobulin predominates in serum as a major acute-phase reactant protein, while in humans e~-macroglobulin fulfills this role. ~4. _, o. 3~ These proteins trap a wide variety of proteases and the protease-macroglobulin complexes are quickly cleared from the circulation. 2~ The measurement of increased general protease activity in serum suggests either that large amounts of general proteases have been released into the serum, which temporarily overwhelms the capacity of the serpins to inactivate them, and/or that a decrease in serum antiproteinase activity is associated with the growth of C6 astrocytoma cells in vivo in this model. Serum antithrombin Ill levels are decreased in Hodgkin's disease, 5 whereas patients with breast cancer have high levels of c~-proteinase inhibitor and c~z-macroglobulin. 2~~7 It is not known in the model under study which of these mechanisms predominates.
Serum Type IV Collagenase Activity
Low levels of type IV collagenase activity have been measured in rat serum. However, the presence of C6 astrocytoma cells growing intracerebrally was associated with two peaks of type IV collagenase activity. A number of compounds are present in the serum which modulate type IV collagenase activity. Cysteine is known to inhibit type IV collagenase activity. Compounds such as TIMP and TIMP-2 may also be present in serum. 2~ Because of their serum concentrations, e~-and r may play critical roles in the control of type IV eollagenase activity in rat serum. Increased c~-and c~2-macroglobulin concentrations may also be present in tumor tissue and may modulate proteolytic activity in this environment. Two potential sources for these proteins in tumor tissue are possible.
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Astrocyte subpopulations ~2 and primary organ cultures of human glioblastoma multiforme tissue ~ secrete c~2-macroglobulin; therefore, both astrocytes and malignant glioma cells may be sources of these proteins. Increased macromolecular permeability is associated with the growth of C6 astrocytoma cells in the spheroid implantation modelfl 'j~ This increased permeability may allow large proteins, such as ~-and ~2-macroglobulin, access to the extracellular space surrounding tumor cells, where they may play a role in modulating proteolytic activity. There appear to be a number of events that modulate both general proteolytic and type IV collagenase activity in serum; these systems seem to be overwhelmed for short periods during the growth of C6 astrocytoma spheroids in vivo.
Sources (?/'Increased Proteolytic Activity
During the in vivo growth of C6 astrocytoma cells in the spheroid implantation model, tumor tissue, peritumoral tissue, and contralateral hemispheric tissue contain elevated levels of proteolytic activity; 34 therefore, these tissues could be a source for the increased serum proteolytic activity observed. In that study, general protease activity from tumor tissue peaked on Day 11 and maximum type IV collagenase activity occurred on Day 13 after spheroid implantation. Figure 3 illustrates the relationship between tumor tissue levels of these enzymatic activities found in that study 34 and serum levels obtained in the present study. The second peak of activity in serum for both general protease and type IV collagenase activity occurs about 2 days after maximum cerebral tumor activity; however, the first peak of serum proteolytic activity is not preceded by elevated cerebral tumor activity. Although the percentage of total general protease and type IV collagenase activity that is extracellular in this model is not known, it is conceivable that the second serum peak of proteo[ytic activity is a reflection of the extraceUular release of activity from tumor cells and/or other tissues containing increased enzyme activity in this model. The increased levels of proteolytic activity in the peritumoral region may also be the result of extracel[ular enzymatic activity that originated in the tumor mass. Figure 4 represents a hypothesis advanced to explain the results outlined in this study. Shortly after the spheroid is implanted into brain tissue, the tumor signals endothelial cells via one or more modulating (growth) factors to up-regulate their production of general protease and type IV collagenase activity and/or down-regulate their production of inhibitors such as TIMP. Endothelial cell lines derived from human non-neoplastic cerebral tissue growing in monolayer culture have been shown to release general protease and type IV collagenase activity (RF Del Maestro, unpublished data). This may result in local degradation of the basement membrane and represents one of the initiation steps of angiogenesis. This degradation must be regulated since later stages of tumor growth, tumor mierovessels may be relatively established and continued tumor growth may occur along established normal blood vessels with a significantly reduced dependence on proteolytic activity. ~~~2 If this model can be extrapolated to human malignant glial tumors, it would predict first, that it may be difficult to use a single serum time point of proteolytic activity as a biochemical marker for an established tumor; and second, that frequent assessments of serum proteolytic activity may be valuable in monitoring recurrent tumor growth after surgical removal and/ or adjuvant therapies.
Conceptual Model
If ongoing characterization studies define specific serum enzymes that are elevated during the initiation or propagation phases of tumor growth, this result may be of value in the early detection of recurrent tumor and in delineating the initial stages in the growth of metastatic lesions.
